Algeta ASA (OSE:ALGETA), the cancer therapeutics company, announces today that it has entered into a global agreement with Bayer for the development and commercialization of Algeta's first-in-class ...

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today! OSLO, NORWAY--(Marketwired - August 19, 2013) - Algeta ASA (OSE: ALGETA), a company focused on the ...

German pharmaceutical group Bayer offered to buy Norway's Algeta, its partner for a new prostate cancer treatment, for $2.4 billion, a 27 percent premium to the stock's last close, Algeta said on ...

Alpharadin is a first-in-class, highly targeted alpha-pharmaceutical under clinical evaluation to improve survival in patients with bone metastases from advanced prostate cancer. Its localised action ...

It’s going to cost an extra half-a-billion dollars, but German drug giant Bayer AG (BAYRY) said Thursday that has reached an agreement to acquire its Norwegian-based partner Algeta for $2.9 billion.

OSLO/FRANKFURT (Reuters) - German drug firm Bayer (GER:BAYN) has clinched a $2.9 billion (1.7 billion pounds) deal to take over Norwegian cancer drug maker Algeta (OSL:ALGETA) after being tendered ...

Algeta and Ablynx enter into a research collaboration to evaluate the potential of novel alpha-pharmaceuticals comprising thorium-227 conjugated to tumor-targeting Nanobodies® Oslo, Norway, and Ghent, ...

Shares in Algeta, the Norwegian pharmaceutical company that specialises in cancer medicine, are up more than 30 per cent this morning after it confirmed in a statement to the Oslo stock exchange that ...

The logo of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals is pictured on the front of its building in Berlin April 28, 2011. REUTERS/Fabrizio Bensch FRANKFURT/OSLO (Reuters) - Bayer ...

Algeta ASA and Ablynx have announced a research collaboration to evaluate a novel Targeted Thorium Conjugate (TTC) based on combining Algeta’s proprietary thorium-227 alpha-pharmaceutical payload with ...

Presentations, where applicable, will be available to download at www.algeta.com following these events. About Algeta Algeta is a company focused on developing novel targeted therapies for patients ...

Oslo, Norway, 4 June 2012 - Algeta ASA (OSE: ALGETA) announces that updated data from the pivotal phase III ALSYMPCA trial for its investigational drug Alpharadin (radium-223 dichloride[1] (#ftn1)) ...